Bone-targeting macromolecular therapeutics

被引：202

作者：

Wang, D

Miller, SC

Kopecková, P

Kopecek, J ^{[1
]}

机构：

[1] Univ Utah, CCCD, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84112 USA

[2] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA

[3] Univ Utah, Div Radiobiol, Salt Lake City, UT 84112 USA

来源：

ADVANCED DRUG DELIVERY REVIEWS | 2005年 / 57卷 / 07期

关键词：

bone-targeting; drug delivery; HPMA copolymer; hydroxyapatite; metalloproteinases (MMPs); cathepsin K; polyethylene glycol (PEG); osteoporosis; cancer bone metastasis; rheumatoid arthritis;

D O I：

10.1016/j.addr.2004.12.011

中图分类号：

R9 [药学];

学科分类号：

1007 [药学];

摘要：

Musculoskeletal diseases such as osteoporosis are recognized as major public health problems worldwide. Many novel therapeutic agents have been identified for the treatment of these diseases. However, the majority of them are not specific to hard tissue, resulting significant toxicity. Bone-targeting drug delivery systems based on water-soluble polymers can specifically direct candidate drugs to bone thereby reducing side effects due to non-specific tissue interactions. Incorporation of a targeting moiety, a drug release mechanism, drug selection and optimization of the polymer carrier are all essential elements in the development of bone-targeting macromolecular therapeutics. Successful clinical application of this approach can significantly contribute to the development of treatments for many musculoskeletal diseases. (c) 2005 Elsevier B.V. All rights reserved.

引用

页码：1049 / 1076

页数：28

共 199 条

[1]

AVIDITY OF THE TETRACYCLINES FOR THE CATIONS OF METALS [J].